Menu Search
Equities

Stratec Se

SBS:DUS

Stratec Se

Actions
  • Price (EUR)30.95
  • Today's Change0.000 / 0.00%
  • Shares traded300.00
  • 1 Year change-31.90%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024 18:32 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Stratec SE is a Germany-based company engaged in the development and manufacture of fully automated systems based on its own patented technologies for its partners in the fields of in-vitro diagnostics and life sciences in Germany and internationally. Its business activities are divided into three segments: Instrumentation, which designs and manufactures fully automated analyzer systems for its clinical diagnostics and biotechnology customers; Diatron, which offers systems, system components, consumables, and tests for the low throughput hematology and clinical chemistry applications, and Consumables, which develops and sells scientific materials, such as nucleic acid purification and designs and produces smart consumables in the fields of diagnostics, life sciences, and medical technology. In addition, the Company develops workflow software for networking various analyzer systems, as well as develops and sells scientific materials and technologies.

  • Revenue in EUR (TTM)250.54m
  • Net income in EUR10.01m
  • Incorporated2018
  • Employees1.46k
  • Location
    Stratec SeGewerbestr. 37BIRKENFELD 75217GermanyDEU
  • Phone+49 708279160
  • Fax+49 70 827916999
  • Websitehttps://www.stratec.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.